Call on Personalised Medicine

European Commission publishes final Horizon 2020 work programme for “Health, demographic change and well-being”.

The call on Personalised Medicine was published on 14 October, with some topics open for submission of proposals as of 20 October. These include for example:

– SC1-HCO-02-2016: Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine – this call aims to provide pan-European quality assurance schemes and guidelines for pre-analytical procedures – such as sample collection, handling, transportation, processing and storing of clinical samples – and/or harmonisation and quality assurance of diagnostic practice. (Deadline: 13 April 2016)

– SC1-PM-09-2016: New therapies for chronic diseases – this call aims to support the development of innovative and effective new therapeutic approaches. Proposals should focus on clinical trials, supporting proof of concept of clinical safety and efficacy in humans of novel therapies, or the optimisation of available therapies (Deadline: 13 April 2016)

– SC1-PM-11-2016-2017: Clinical research on regenerative medicine – this call aims to test new regenerative medicine therapies which are ready for clinical (in-patient) research and should focus on one specific clinical phase of work. Clinical work should represent the core of the proposal (Deadline: 13 April 2016)

– SC1-PM-21-2016:Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries – this call aims to fund proposals which seek to replicate and scale up a comprehensive intervention in the field of health systems that is innovative, supported by sufficient documented evidence, which has proven to make health systems and services more responsive, person-centred, safe, effective, and efficient (Deadline: 13 April 2016)

– SC1-PM-01-2016:Multi omics for personalised therapies addressing diseases of the immune system – this call aims to contribute to the development of new targeted therapies for diseases of the immune system through selection of relevant biomarkers by integration and use of high quality genome, epigenome, proteome, metabolome, microbiome data combined with innovative imaging, functional, structural and lifestyle/ environmental data (Deadline: 13 April 2016)

Some forthcoming topics for proposals to keep in mind:
– SC1-PM-03-2017: Diagnostic characterisation of rare diseases (Planned opening: 29 July 2016)
– SC1-PM-08-2017: New therapies for rare diseases (Planned opening: 29 July 2016)
– SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population (Planned opening: 29 July 2016))
– SC1-PM-16-2017: In-silico trials for developing and assessing biomedical products (Planned opening: 8 November 2016)

Access the 2016-2017 “Health, demographic change and well-being” work programme here.
Access the call on personalised medicine here.